[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545645":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":30,"responsibleParty":47,"collaborators":20,"id":49,"slug":20,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":20,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":20,"enrollmentInfo":57,"targetDuration":20,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":70,"whyStopped":20,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Adagio Medical","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"VT Cryoablation Arm","EXPERIMENTAL","all subjects will receive a cryoablation procedure with the VT System and be followed up for 6-month",[13],"Device: VT Cryoablation System",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","VT Cryoablation System","All subjects will receive a cryoablation procedure using the VT Cryoablation System (catheter, stylets, and console)",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Nabil Jubran","CONTACT","(949) 348-1188","njubran@adagiomedical.com",{"name":28,"role":24,"phone":25,"phoneExt":20,"email":29},"Doug Kurschinski","dkurschinski@adagiomedical.com",[31],{"facility":32,"status":20,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Essex Cardiothoracic Centre","Basildon","Essex","SS16 5NL","United Kingdom","UK",{"type":39,"coordinates":40},"Point",[41,42],0.45782,51.56844,{"lat":42,"lon":41},[45],{"name":46,"role":24,"phone":20,"phoneExt":20,"email":20},"Neil Srinivasan",{"type":48,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100545645",false,"NCT06384599","VT Cryoablation System Post-Market Clinical Follow-up (PMCF) Study","Adagio Medical VT Cryoablation System Post-Market Clinical Follow-up (PMCF) Study","Inclusion Criteria:\n\n* IC 1 Male or female the ages of ≥ 18 years\n* IC 2 Planned ablation procedure according to the indication for use of the Adagio VT Cryoablation System\n* IC 3 Subject willing to comply with study requirements and give informed consent\n* IC4 Subject has or will be receiving an ICD prior to hospital discharge\n\nExclusion Criteria:\n\n* EC 1 In the opinion of the investigator, any known contraindication to a ventricular tachycardia procedure with the Adagio VT Cyroablation System as indicated in the device Instructions For Use (IFU)\n* EC 2 Subject is enrolled in a study that has not been approved for concurrent enrollment by the sponsor\n* EC 3 Any other condition that, in the judgement of the investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, terminal illness with a life expectancy of less than six months, extensive travel away from the research center)","ALL","18 Years",{"count":58,"type":59},130,"ESTIMATED","INTERVENTIONAL",[62],"NA","The PMCF is a prospective, single-arm, multi-center, controlled study of up to 130 patients designed to collect safety and performance data regarding the use of the Adagio VT Cryoablation System in the treatment of recurrent ventricular tachycardia.",[65],"Ventricular Tachycardia",[67,68,69],"Monomorphic Ventricular Tachycardia","VT","Cryoablation","NOT_YET_RECRUITING","2026-04-06",{"date":73,"type":74},"2026-04-09","ACTUAL",{"date":76,"type":59},"2026-09-01",{"date":78,"type":59},"2027-09-01",{"name":5,"class":6},1]